A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE015 (POL) · Dr. Ito
consented 2022-02-24
AEs
4
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-07-04 (study day 120); relationship: N
moderate
assessed
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-08-21 (study day 168); relationship: N
mild
assessed
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-09-22 (study day 200); relationship: not assessed
moderate
assessed
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-10-23 (study day 231); relationship: N
Data queries
No data queries.